Company news
Tasly Pharmaceutical Group Co. Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Report for Q3 2026
October 23, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Termination of an R&D Project and Provision for Asset Impairment
October 23, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Resolutions of the 26th Meeting of the 9th Board of Directors
October 23, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Obtaining Drug Registration Certificate by Subsidiary
October 15, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Obtaining the Drug Clinical Trial Approval Notice
October 14, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Election of Employee Director
October 12, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Obtaining Drug Registration Certificate by Subsidiary
October 9, 2026
(600535)"TASLY PHARMACEUTICAL GROUP CO., LTD."Announcement on Implementation of Dividend Distribution for the First Half of 2026
October 8, 2026
Announcement on Resolutions of the 25th Meeting of the 9th Board of Directors
September 24, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
September 11, 2026
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction
August 28, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
August 27, 2026
Announcement on Subsidiary Obtaining the Notice of Approval for Clinical Trial
August 21, 2026
Announcement on Amendments to the Articles of Association
August 10, 2026
Announcement on a Wholly-owned Subsidiary's Receipt of Clinical Trial Notice for the Extension of the Treatment Time Window for the Acute Ischemic Stroke Indication of Recombinant Human Pro-urokinase for Injection
July 17, 2026
Announcement on Semi-annual Performance for 2026
July 14, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
June 25, 2026
Announcement on Obtaining Drug Registration Certificate by Subsidiary
June 15, 2026
Announcement on Remuneration Plan for Directors and Senior Management Members in 2026
June 8, 2026
Announcement on Implementation of Dividend Distribution for 2025
May 21, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
May 18, 2026
Announcement on Change of Accounting Policies
April 24, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
April 17, 2026
Announcement on Guarantee Estimate for 2026
March 23, 2026
Announcement on Annual Key Operating Data Report for 2025
March 19, 2026
Announcement on Resignation of Senior Management Member
March 6, 2026
Preliminary Earnings Estimate for 2025
February 6, 2026
Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard
January 24, 2026
Announcement on Resolutions of the 6th Extraordinary General Meeting in 2025
December 26, 2025
Announcement on Estimated Related Party Transactions of Daily Operations in 2026
December 9, 2025
Announcement on Convening the Q3 2025 Performance Briefing
November 26, 2025
Announcement on Resolutions of the 15th Meeting of the 9th Board of Directors
October 24, 2025
Announcement on Obtaining Drug Registration Certificate for Wenjing Decoction Granules
October 13, 2025
Announcement on Resolutions of the 5th Extraordinary General Meeting in 2025
October 10, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
October 9, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trial
September 24, 2025
Announcement on Acquisition of Drug Registration Certificate for New Indication of Acute Ischemic Cerebral Stroke of the Wholly-owned Subsidiary's Reocmbinant Human Prourokinase for Injection
September 22, 2025
Announcement on Using Idle Funds to Purchase Bank Financial Products
September 17, 2025
Announcement on Progress in Providing Guarantee for Subsidiary
September 15, 2025
Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction
September 5, 2025
Announcement on Resolutions of the 13th Meeting of the 9th Board of Directors
September 2, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 20, 2025
2025 Semi-annual Report
August 15, 2025
Announcement on Appointment of Senior Management Members
August 6, 2025
Announcement on Expiration of Duration and Termination of the Employee Stock Ownership Plan
July 23, 2025
Announcement on the Progress of Drug Registration Application
July 18, 2025
Announcement on Resolutions of the 10th Meeting of the 9th Board of Directors
July 15, 2025
Announcement on Obtaining Drug Registration Certificate for D-Glucosamine Sulfate Capsules by Wholly-owned Subsidiary
June 10, 2025
Announcement on Obtaining Drug Registration Certificate for Torasemide Injection by Wholly-owned Subsidiary
May 28, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
May 14, 2025